A man of 52 was referred after four months of right-sided chest pain with dyspnoea and lethargy. He was a nonsmoker who worked as a toolmaker and had no known exposure to asbestos. CT showed irregular pleural thickening extending to the mediastinal and diaphragmatic pleura, and percutaneous biopsy confirmed malignant mesothelioma. He was anaemic (haemoglobin 9.1 g/dL) with a raised white cell count (15.5610 9 /L) and platelet count (1171610 9 /L). Urea and creatinine were normal but serum potassium was slightly raised at 5.5 mmol/L. He was referred to a cancer centre for palliative chemotherapy, by which time his haemoglobin had dropped to 6.9 g/dL; his white cell count had risen to 21610 9 /L and the platelet count to 1400610 9 /L. Serum folate and vitamin B12 levels were normal, serum ferritin raised. After transfusion of blood he was treated with mitomycin, vinblastine and cisplatin (MVP). At the cancer centre his serum potassium was 7.1 mmol/L (sodium, creatinine and cortisol normal). After treatment with intravenous glucose and insulin he was started on oral Calcium Resonium (calcium polystyrene sulphonate), an ion-exchange resin. By now the white cell count was 31.5610 9 /L and the platelet count 1735610 9 /L (it peaked at 2000).
After four three-weekly cycles of chemotherapy the patient did not seem to be responding, and six months after initial diagnosis he was referred back to his local hospital for follow-up and palliative care. The serum potassium was then rechecked and proved to be 6.2 mmol/L; however, a simultaneous plasma potassium was only 5.1 mmol/L confirming the clinical suspicion of pseudohyperkalaemia secondary to thrombocytosis. Calcium Resonium was stopped. Over the next few months his health improved, he returned to full-time work and his chest radiograph showed minimal residual tumour. During this remission the serum potassium dropped to 5.0 mmol/L, haemoglobin rose to 12.0 g/L, WBC fell to 13.6610 9 /L and platelets fell to 456610 9 /L. After eighteen symptom-free months the tumour recurred and he did not respond to further chemotherapy. On the day he died he was brought to his local hospital because of chest pain and dyspnoea. Renal function was normal, platelet count 1400610 9 /L, serum potassium 6.8 mmol/L. While awaiting his case notes and being unaware of his previous diagnosis of pseudohyperkalaemia, the admitting team treated him with intravenous glucose and insulin to lower the potassium.
COMMENT
The thrombocytosis associated with this patient's mesothelioma caused an in-vitro rise in serum potassium. Suspicion of pseudohyperkalaemia was confirmed when plasma potassium proved to be substantially lower and when both platelet count and serum potassium fell with chemotherapy.
There is a recognized association between malignant mesothelioma and thrombocytosis. 1 The rise in platelets and white cell count is thought to be largely due to increased production of interleukin 6 by the tumour, 2,3 with other thrombopoietic substances possibly involved as well. 4 The anaemia in our patient was probably that of 'chronic disease' since it was associated with a high ferritin level and improved when his tumour regressed.
Thrombocytosis can be associated with a raised serum potassium, 5,6 but we are not aware of this having been reported in mesothelioma. The mechanism of the hyperkalaemia is probably in-vitro release of potassium from cells undergoing lysis, the true plasma potassium in vivo being normal. This phenomenon is easily forgotten; the present patient was treated with intravenous glucose and insulin on two occasions to lower the potassium and had also been treated with an oral ion exchange resin. We know of another patient with pseudohyperkalaemia (secondary to thrombocytosis and myeloproliferative disorder) who has likewise been given glucose and insulin infusions on two occasions, unnecessarily.
